Piper Jaffray has issued a report reiterating the Overweight Rating on Salix Pharmaceuticals SLXP.
ACcording to the report, "We spent yesterday with Salix senior management meeting with investors. We came away with even greater confidence that there is a reasonable path forward for Xifaxan in irritable bowel syndrome (IBS), and with greater confidence in the overall trajectory of the in-market product portfolio."
SLXP has a $47 Price Target and closed at $38.79 a share yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in